Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2004
Business Overview: NAI provides private label contract manufacturing services for vitamins, minerals, and nutritional supplements, alongside a direct-to-consumer marketing program. Operations are based in San Marcos and Vista, California, with a subsidiary manufacturing facility in Manno, Switzerland (NAIE). The company holds TGA and NSF GMP certifications.
Key Financial Metrics
| Metric | Fiscal 2004 | Fiscal 2003 |
|---|---|---|
| Net Sales | $78,534,000 | $55,962,000 |
| Gross Profit | $18,570,000 | $13,181,000 |
| Gross Margin | 24% | 24% |
| Net Income | $3,000,000 | $1,105,000 |
| Diluted EPS | $0.48 | $0.18 |
| Operating Cash Flow | $3,284,000 | $3,295,000 |
| Total Debt | $4,672,000 | $3,000,000 (approx.) |
| Cash & Equivalents | $7,495,000 | $5,482,000 |
| Working Capital | $17,468,000 | $12,321,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 40% to $78.5 million, driven primarily by a 50% increase in private label contract manufacturing sales ($68.5M vs $45.8M). Direct-to-consumer sales remained flat at $10.0M.
- Profitability: Net income surged 171% to $3.0 million. This was aided by a reversal of a $1.6 million valuation allowance on deferred tax assets, which provided a significant tax benefit.
- Customer Concentration: The top two customers (NSA International, Inc. and Mannatech, Inc.) accounted for approximately 70% of total net sales (40% and 30% respectively).
- Debt Structure: In May 2004, NAI refinanced its debt with a new $12.0 million credit facility, consisting of an $8.0 million working capital line and $4.0 million in term loans.
- Capital Expenditures: CapEx increased significantly to $3.3 million, primarily for manufacturing equipment and the build-out of 46,000 square feet of new space in Vista, CA.
Guidance, Outlook, and Risks
- Outlook: Management plans to grow and diversify the customer base, improve operational efficiency, and invest heavily in facility expansion. They anticipate capital expenditures of at least $6.5 million in fiscal 2005.
- Tax Holiday: The Swiss subsidiary (NAIE) operates under a five-year tax holiday expiring June 30, 2005. Post-expiration, the effective tax rate for NAIE is expected to rise from ~5% to ~23%.
- Key Risks:
- Customer Dependency: Loss of NSA International or Mannatech would materially impact financial results.
- Supply Chain: Reliance on a limited number of raw material suppliers; Carrington Laboratories accounted for 33% of purchases.
- Regulatory: Subject to extensive FDA and international regulations regarding product claims and manufacturing practices.
- Direct-to-Consumer: Sales rely on key personalities (e.g., Dr. Cherry); negative publicity or inability to perform could harm revenue.
Investor Verification Checklist
- Verify the sustainability of revenue growth from the top two customers (NSA and Mannatech) given the 70% concentration risk.
- Assess the impact of the Swiss tax holiday expiration in June 2005 on future effective tax rates and net income.
- Monitor the progress and cost overruns of the Vista, CA facility expansion and its impact on cash flow.
- Review the company's ability to diversify its supplier base to mitigate the 33% reliance on Carrington Laboratories.
- Confirm the effectiveness of the new $12M credit facility in supporting the projected $6.5M capital expenditure plan for fiscal 2005.